Emotional Processing & Oxytocin Mechanisms in Premenstrual Dysphoric

Status Active, not recruiting

Clinical Trial Summary

This research study will look at differences among women with severe premenstrual mood symptoms. One goal of this study is to look at how the brains of two groups of these women respond to emotional information. The two groups are women who were abused early in life and women who were not. The study will use a brain scan to look at how certain areas of the brain respond to the viewing of words and pictures. Another goal of this study is to look at the effects of taking a nasal spray containing oxytocin (a hormone made in the brain) on those same brain areas during the viewing of words and pictures. Also, the investigators will look at whether oxytocin given in the nose improves premenstrual mood symptoms.

Clinical Trial Description

Purpose: The primary objective of this pilot study is to begin to identify the central networks using functional neuroimaging techniques that may contribute to the greater impairment in emotion regulation, interpersonal relationships, and marital and family function in women with premenstrual dysphoric disorder (PMDD) who also have a history of early life abuse (ELA).

Based on the evidence that the mammalian neuropeptide oxytocin (OT), best known for its role in lactation and parturition, plays a seminal role in social affiliation, emotion regulation, attachment, maternal behavior, trust, and protection against stress; and because OT neural pathways and receptors are prominently expressed in brain regions involved in emotion regulation and maternal/affiliative behavior; the study will: 1) use intranasal OT administration as a probe to assess whether it modifies activation of central regions involved in emotion regulation in response to cognitive emotional tasks; and 2) whether daily intranasal OT administration during the premenstrual phase improves symptoms in women with PMDD with or without a history of ELA. ;

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02508103
Study type	Interventional
Source	University of North Carolina, Chapel Hill
Contact
Status	Active, not recruiting
Phase	Phase 2/Phase 3
Start date	July 2015
Completion date	December 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03862469` - Premenstrual Hormonal and Affective State Evaluation (PHASE) Project	N/A
Active, not recruiting	`NCT00536198` - Evaluating the Effectiveness of Sertraline in Treating Women With Premenstrual Dysphoric Disorder	N/A
Completed	`NCT03449979` - Single Session of tACS in a Depressive Episode	N/A
Completed	`NCT00516113` - A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine in Premenstrual Dysphoria	Phase 4
Recruiting	`NCT05098574` - Oral Contraceptives for Treating Premenstrual Dysphoric Disorder in Bipolar Disorder	Phase 2
Withdrawn	`NCT04123483` - EnBrace HR for PMS With Prominent Mood Symptoms or Menstrual Related Mood Disorders	Phase 4
Completed	`NCT00518570` - Levetiracetam in the Treatment of Patients With Premenstrual Dysphoric Disorder (PMDD)	N/A
Not yet recruiting	`NCT01217775` - Intranasal PH80 Spray for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder	Phase 3
Terminated	`NCT02362191` - Targeting Inter-Hemispheric Alpha Coherence With tACS To Treat PMDD	N/A
Completed	`NCT00678574` - The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder	Phase 4
Active, not recruiting	`NCT05327075` - Premenstrual Dysphoric Disorder:Knowledge,Attitude and Practice Among Egyptian Females
Not yet recruiting	`NCT02448836` - Deep Transcranial Magnetic Stimulation (dTMS) for the Treatment of Premenstrual Dysphoric Disorder (PMDD)	N/A
Completed	`NCT01799733` - Alternative Treatments for Premenstrual Dysphoric Disorder	N/A
Completed	`NCT06227676` - Effect of 'Cramp Bites' on Period Cramps in Women Aged 18-25	Phase 2/Phase 3
Completed	`NCT00927095` - Continuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD)	Phase 4
Completed	`NCT00089414` - Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives	Phase 2
Not yet recruiting	`NCT06462391` - Adapting and Piloting Acceptance and Commitment Therapy (ACT) for Severe Premenstrual Mood Symptoms	N/A
Completed	`NCT01875718` - A Phase I/II Study to Evaluate UC1010 Treatment in Premenstrual Dysphoric Disorder (PMDD)	Phase 1/Phase 2
Completed	`NCT06136104` - The Effects of Mixhers HERTIME Supplements on Menstrual Symptoms	N/A
Completed	`NCT01385709` - The Influence of the Menstrual Cycle on Lithium and Sertraline Blood Levels	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Emotional Processing and Oxytocin Mechanisms in Premenstrual Dysphoric Disorder: A Pilot Study

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms